The market for favipiravir is expected to grow at a CAGR of around 4.4% from 2020 to 2027 and expected to reach the market value of around US$ 213.5 Mn by 2027.
Favipiravir is an antiviral drug that was initially approved for the treatment of influenza in Japan and was resistant to oseltamivir and zanamivir therapies. It’s a pyrazinecarboxamide derivative with Molecular Formula C5H4FN3O2. It can be administered orally or intravenously and inhibits viral replication of RNA viruses by interfering with viral RNA polymerase function. These are used in the treatment of Influenza A and B viruses, ebola virus, yellow fever, Nipah virus, and COVID-19 (on trial) and are available in packaging type of 20 tablets/box, and 40 tablets/box among others.
Market Dynamics
The rising prevalence of RNA viral infections such as influenza, ebola, among others is driving the market growth. The promising clinical trial studies pertaining to the therapeutic efficacy and safety of favipiravir in the treatment of coronavirus infection is propelling the market growth. Favipiravir now in 2020 approved by some of the countries as a drug for prevention and treatment of COVID-19 as Covid-19 shares the common symptoms with influenza virus. Furthermore, the increasing investment in R&D activities across the healthcare sector is projected to provide potential growth over the estimated period.
On the other side, high capital investment and restrictions are projected to limit the growth over the forecast period from 2020 to 2027.
Hospital segment has registered a major revenue share in the global market
By the end-user, the hospital segment is leading the market with major revenue share (%). The use of favipiravir is intended for chronic diseases whose patients require hospitalization and serious treatment, which are the factors supporting the segmental market value. The rapid development of hospitals in developing and underdeveloped economies is propelling the segmental market value.
Asia Pacific accounted for the dominating share in the Favipiravir market
In 2019, Asia Pacific is leading the market with maximum share (%) in terms of revenue (US$ Mn) and also projected to maintain its dominance over the estimated period from 2020 to 2027. The presence of major players in the region such as Cipla Limited, Fujifilm Toyama Chemical Co., Ltd, Glenmark Pharmaceuticals, and Lasa Supergenerics Limited are particularly supporting the regional market value. The major economies of the region including Japan, China, and India are major contributors to regional market growth. The increasing disposable income and rapid advancement in the healthcare sector in terms of infrastructure, research proposals, and medicines is bolstering the regional market value. The increasing investment in R&D activities especially for COVID-19 by major players is further contributing to the regional market growth. Moreover, the region is also anticipated to exhibit the fastest growth with major CAGR (%) throughout the estimated timeframe from 2020 to 2027.
The players profiled in the report include Beacon Pharmaceuticals (Bangladesh), Beximco Pharmaceuticals Limited (Bangladesh), ChemRar Group, Cipla Limited (India), Fujifilm Toyama Chemical Co., Ltd (Japan), Glenmark Pharmaceuticals (India), Hisun Pharm (China), Lasa Supergenerics Limited (India), Medivector, Inc (US), Sihuan Pharmaceuticals, and Zhejiang Hisun Pharmaceutical Co., Ltd (China). The major favipiravir players were involved in strategic developments for escalating the profit share in regional as well as global market. The major investments were announced for the technological advancements associated with the changing consumer need for the favipiravir. The rapidly increasing number of COVID-19 disease cases across the globe is pushing global players to develop and supply vaccines to restrict the increasing number of coronavirus cases.
Market Segmentation
Market By Disease
Influenza Viruses
Coronavirus (COVID-19)
Severe Acute Respiratory Syndrome (SARS)
Ebola
Others
Market By End-User
Hospital
Clinics
Drug Store
Others
Market By Geography
North America
Europe
- UK
- Germany
- France
- Spain
- Rest of Europe
Asia-Pacific
- China
- Japan
- India
- Australia
- South Korea
- Rest of Asia-Pacific
Latin America
- Brazil
- Mexico
- Rest of Latin America
Middle East & Africa
- GCC
- South Africa
- Rest of Middle East & Africa
Table Of Content:
CHAPTER 1. INDUSTRY OVERVIEW
1.1. Definition and Scope
1.1.1. Definition of Favipiravir
1.1.2. Market Segmentation
1.1.3. List of Abbreviations
1.2. Summary
1.2.1. Market Snapshot
1.2.2. Favipiravir Market By Disease
1.2.2.1. Global Favipiravir Market Revenue and Growth Rate Comparison By Disease (2020-2027)
1.2.2.2. Global Favipiravir Market Revenue Share By Disease in 2019
1.2.2.2.1. Influenza Viruses
1.2.2.2.2. Coronavirus (COVID-19)
1.2.2.2.3. Severe Acute Respiratory Syndrome (SARS)
1.2.2.2.4. Ebola
1.2.2.2.5. Others
1.2.3. Favipiravir Market By End-User
1.2.3.1. Hospital
1.2.3.2. Clinics
1.2.3.3. Drug Store
1.2.3.4. Others
1.2.4. Favipiravir Market By Geography
1.2.4.1. Global Favipiravir Market Revenue and Growth Rate Comparison by Geography (2020-2027)
1.2.4.2. North America Favipiravir Market Revenue and Growth Rate(2020-2027)
1.2.4.3. Europe Favipiravir Market Revenue and Growth Rate(2020-2027)
1.2.4.4. Asia-Pacific Favipiravir Market Revenue and Growth Rate(2020-2027)
1.2.4.5. Latin America Favipiravir Market Revenue and Growth Rate(2020-2027)
1.2.4.6. Middle East and Africa (MEA) Favipiravir Market Revenue and Growth Rate(2020-2027)
CHAPTER 2. MARKET DYNAMICS AND COMPETITION ANALYSIS
2.1. Market Drivers
2.2. Restraints and Challenges
2.3. Growth Opportunities
2.4. Porter’s Five Forces Analysis
2.4.1. Bargaining Power of Suppliers
2.4.2. Bargaining Power of Buyers
2.4.3. Threat of Substitute
2.4.4. Threat of New Entrants
2.4.5. Degree of Competition
2.5. Value Chain Analysis
2.6. Cost Structure Analysis
2.6.1. Raw Material and Suppliers
2.6.2. Manufacturing Process Analysis
2.7. Regulatory Compliance
2.8. Competitive Landscape, 2019
2.8.1. Player Positioning Analysis
2.8.2. Key Strategies Adopted By Leading Players
CHAPTER 3. MANUFACTURING PLANTS ANALYSIS
3.1. Capacity and Commercial Production Date of Global Pure Cashmere Major Manufacturers in 2019
3.2. Manufacturing Plants Distribution of Global Pure Cashmere Major Manufacturers in 2019
3.3. R&D Status and Technology Source of Global Pure Cashmere Major Manufacturers in 2019
3.4. Raw Materials Sources Analysis of Global Pure Cashmere Major Manufacturers in 2019
CHAPTER 4. Favipiravir MARKET By Disease
4.1. Global Pure Cashmere Revenue By Disease
4.2. Influenza Viruses
4.2.1. Market Revenue and Growth Rate, 2020 - 2027 ($Million)
4.2.2. Market Revenue and Forecast, By Region, 2020 - 2027 ($Million)
4.3. Coronavirus (COVID-19)
4.3.1. Market Revenue and Growth Rate, 2020 - 2027 ($Million)
4.3.2. Market Revenue and Forecast, By Region, 2020 - 2027 ($Million)
4.4. Severe Acute Respiratory Syndrome (SARS)
4.4.1. Market Revenue and Growth Rate, 2020 - 2027 ($Million)
4.4.2. Market Revenue and Forecast, By Region, 2020 - 2027 ($Million)
4.5. Ebola
4.5.1. Market Revenue and Growth Rate, 2020 - 2027 ($Million)
4.5.2. Market Revenue and Forecast, By Region, 2020 - 2027 ($Million)
4.6. Others
4.6.1. Market Revenue and Growth Rate, 2020 - 2027 ($Million)
4.6.2. Market Revenue and Forecast, By Region, 2020 - 2027 ($Million)
CHAPTER 5. Favipiravir MARKET By End-User
5.1. Global Pure Cashmere Revenue By End-User
5.2. Hospital
5.2.1. Market Revenue and Growth Rate, 2020 - 2027 ($Million)
5.2.2. Market Revenue and Forecast, By Region, 2020 - 2027 ($Million)
5.3. Clinics
5.3.1. Market Revenue and Growth Rate, 2020 - 2027 ($Million)
5.3.2. Market Revenue and Forecast, By Region, 2020 - 2027 ($Million)
5.4. Drug Store
5.4.1. Market Revenue and Growth Rate, 2020 - 2027 ($Million)
5.4.2. Market Revenue and Forecast, By Region, 2020 - 2027 ($Million)
5.5. Others
5.5.1. Market Revenue and Growth Rate, 2020 - 2027 ($Million)
5.5.2. Market Revenue and Forecast, By Region, 2020 - 2027 ($Million)
CHAPTER 6. NORTH AMERICA Favipiravir MARKET BY COUNTRY
6.1. North America Favipiravir Market Revenue and Growth Rate, 2020 - 2027 ($Million)
6.2. North America Favipiravir Market Revenue Share Comparison, 2020 & 2027 (%)
6.3. U.S.
6.3.1. U.S. Favipiravir Market Revenue and Forecast By Disease, 2020 - 2027 ($Million)
6.3.2. Market Revenue and Forecast By End-User, 2020 - 2027 ($Million)
6.4. Canada
6.4.1. Market Revenue and Forecast By Disease, 2020 - 2027 ($Million)
6.4.2. Market Revenue and Forecast By End-User, 2020 - 2027 ($Million)
CHAPTER 7. EUROPE Favipiravir MARKET BY COUNTRY
7.1. Europe Favipiravir Market Revenue and Growth Rate, 2020 - 2027 ($Million)
7.2. Europe Favipiravir Market Revenue Share Comparison, 2020 & 2027 (%)
7.3. UK
7.3.1. Market Revenue and Forecast By Disease, 2020 - 2027 ($Million)
7.3.2. Market Revenue and Forecast By End-User, 2020 - 2027 ($Million)
7.4. Germany
7.4.1. Market Revenue and Forecast By Disease, 2020 - 2027 ($Million)
7.4.2. Market Revenue and Forecast By End-User, 2020 - 2027 ($Million)
7.5. France
7.5.1. Market Revenue and Forecast By Disease, 2020 - 2027 ($Million)
7.5.2. Market Revenue and Forecast By End-User, 2020 - 2027 ($Million)
7.6. Spain
7.6.1. Market Revenue and Forecast By Disease, 2020 - 2027 ($Million)
7.6.2. Market Revenue and Forecast By End-User, 2020 - 2027 ($Million)
7.7. Rest of Europe
7.7.1. Market Revenue and Forecast By Disease, 2020 - 2027 ($Million)
7.7.2. Market Revenue and Forecast By End-User, 2020 - 2027 ($Million)
CHAPTER 8. ASIA-PACIFIC Favipiravir MARKET BY COUNTRY
8.1. Asia-Pacific Favipiravir Market Revenue and Growth Rate, 2020 - 2027 ($Million)
8.2. Asia-Pacific Favipiravir Market Revenue Share Comparison, 2020 & 2027 (%)
8.3. China
8.3.1. Market Revenue and Forecast By Disease, 2020 - 2027 ($Million)
8.3.2. Market Revenue and Forecast By End-User, 2020 - 2027 ($Million)
8.4. Japan
8.4.1. Market Revenue and Forecast By Disease, 2020 - 2027 ($Million)
8.4.2. Market Revenue and Forecast By End-User, 2020 - 2027 ($Million)
8.5. India
8.5.1. Market Revenue and Forecast By Disease, 2020 - 2027 ($Million)
8.5.2. Market Revenue and Forecast By End-User, 2020 - 2027 ($Million)
8.6. Australia
8.6.1. Market Revenue and Forecast By Disease, 2020 - 2027 ($Million)
8.6.2. Market Revenue and Forecast By End-User, 2020 - 2027 ($Million)
8.7. South Korea
8.7.1. Market Revenue and Forecast By Disease, 2020 - 2027 ($Million)
8.7.2. Market Revenue and Forecast By End-User, 2020 - 2027 ($Million)
8.8. Rest of Asia-Pacific
8.8.1. Market Revenue and Forecast By Disease, 2020 - 2027 ($Million)
8.8.2. Market Revenue and Forecast By End-User, 2020 - 2027 ($Million)
CHAPTER 9. LATIN AMERICA Favipiravir MARKET BY COUNTRY
9.1. Latin America Favipiravir Market Revenue and Growth Rate, 2020 - 2027 ($Million)
9.2. Latin America Favipiravir Market Revenue Share Comparison, 2020 & 2027 (%)
9.3. Brazil
9.3.1. Market Revenue and Forecast By Disease, 2020 - 2027 ($Million)
9.3.2. Market Revenue and Forecast By End-User, 2020 - 2027 ($Million)
9.4. Mexico
9.4.1. Market Revenue and Forecast By Disease, 2020 - 2027 ($Million)
9.4.2. Market Revenue and Forecast By End-User, 2020 - 2027 ($Million)
9.5. Rest of Latin America
9.5.1. Market Revenue and Forecast By Disease, 2020 - 2027 ($Million)
9.5.2. Market Revenue and Forecast By End-User, 2020 - 2027 ($Million)
CHAPTER 10. MIDDLE EAST & AFRICA Favipiravir MARKET BY COUNTRY
10.1. Middle East & Africa Favipiravir Market Revenue and Growth Rate, 2020 - 2027 ($Million)
10.2. Middle East& Africa Favipiravir Market Revenue Share Comparison, 2020 & 2027 (%)
10.3. GCC
10.3.1. Market Revenue and Forecast By Disease, 2020 - 2027 ($Million)
10.3.2. Market Revenue and Forecast By End-User, 2020 - 2027 ($Million)
10.4. South Africa
10.4.1. Market Revenue and Forecast By Disease, 2020 - 2027 ($Million)
10.4.2. Market Revenue and Forecast By End-User, 2020 - 2027 ($Million)
10.5. Rest of Middle East & Africa
10.5.1. Market Revenue and Forecast By Disease, 2020 - 2027 ($Million)
10.5.2. Market Revenue and Forecast By End-User, 2020 - 2027 ($Million)
CHAPTER 11. COMPANY PROFILE
11.1. Beacon Pharmaceuticals
11.1.1. Company Snapshot
11.1.2. Overview
11.1.3. Financial Overview
11.1.4. Product Portfolio
11.1.5. Key Developments
11.1.6. Strategies
11.2. Beximco Pharmaceuticals Limited
11.2.1. Company Snapshot
11.2.2. Overview
11.2.3. Financial Overview
11.2.4. Product Portfolio
11.2.5. Key Developments
11.2.6. Strategies
11.3. ChemRar Group
11.3.1. Company Snapshot
11.3.2. Overview
11.3.3. Financial Overview
11.3.4. Product Portfolio
11.3.5. Key Developments
11.3.6. Strategies
11.4. Cipla Limited
11.4.1. Company Snapshot
11.4.2. Overview
11.4.3. Financial Overview
11.4.4. Product Portfolio
11.4.5. Key Developments
11.4.6. Strategies
11.5. Fujifilm Toyama Chemical Co., Ltd
11.5.1. Company Snapshot
11.5.2. Overview
11.5.3. Financial Overview
11.5.4. Product Portfolio
11.5.5. Key Developments
11.5.6. Strategies
11.6. Glenmark Pharmaceuticals
11.6.1. Company Snapshot
11.6.2. Overview
11.6.3. Financial Overview
11.6.4. Product Portfolio
11.6.5. Key Developments
11.6.6. Strategies
11.7. Hisun Pharm
11.7.1. Company Snapshot
11.7.2. Overview
11.7.3. Financial Overview
11.7.4. Product Portfolio
11.7.5. Key Developments
11.7.6. Strategies
11.8. Lasa Supergenerics Limited
11.8.1. Company Snapshot
11.8.2. Overview
11.8.3. Financial Overview
11.8.4. Product Portfolio
11.8.5. Key Developments
11.8.6. Strategies
11.9. Medivector, Inc
11.9.1. Company Snapshot
11.9.2. Overview
11.9.3. Financial Overview
11.9.4. Product Portfolio
11.9.5. Key Developments
11.9.6. Strategies
11.10. Sihuan Pharmaceuticals
11.10.1. Company Snapshot
11.10.2. Overview
11.10.3. Financial Overview
11.10.4. Product Portfolio
11.10.5. Key Developments
11.10.6. Strategies
11.11. Others
11.11.1. Company Snapshot
11.11.2. Overview
11.11.3. Financial Overview
11.11.4. Product Portfolio
11.11.5. Key Developments
11.11.6. Strategies
CHAPTER 12. RESEARCH APPROACH
12.1. Research Methodology
12.1.1. Initial Data Search
12.1.2. Secondary Research
12.1.3. Primary Research
12.2. Assumptions and Scope
